Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This chapter reviews nanocarriers for acne therapy, highlighting their ability to reduce lesions and inflammation while improving the safety and effectiveness of treatment, though no new clinical results are reported.

This article discusses the potential of topical ruxolitinib as a treatment for alopecia universalis and acknowledges the need for alternatives to systemic JAK inhibitors due to the risk of serious side effects.

This study found that artocarpin delivered via alginate/chitosan microparticles effectively suppressed the growth of hamster flank organs compared to artocarpin in solution form, without significant systemic effects.

Two non-steroidal antiandrogens, RU 58841 and RU 56187, form a common metabolite at different rates, which may influence their effects; RU 56187 could be used for prostate cancer treatment and RU 58841 for acne treatment.

This review discusses the increasing reports of frontal fibrosing alopecia, a form of scarring alopecia, and its potential link to autoimmune disorders, but reports no new clinical results.

This systematic review discusses various topical, oral, injectable, and non-pharmacological treatments for androgenetic alopecia, examining both current and emerging therapeutic options in addressing this common form of hair loss.

Oral and topical tofacitinib can effectively treat severe hair loss with minimal side effects.

This review discusses the topical use of systemic drugs for cutaneous disorders and reports a lack of strong evidence from randomized controlled trials, highlighting the need for larger comparative effectiveness studies.

This study reported that while topical minoxidil exhibits hair regrowth in androgenetic alopecia, oral minoxidil 5 mg/day was more effective than topical forms after six months, with low doses also potentially effective for women and other hair loss types.

This article highlights the need for a comprehensive review of injectable minoxidil for hair loss, as existing treatments primarily focus on topical and oral forms of the medication.

This article reviews various types of primary cicatricial alopecias and emphasizes the importance of accurate diagnosis to improve management strategies, particularly detailing remaining lymphocytic forms and expanding on neutrophilic and mixed types.

This study found that polymeric nanoparticles may effectively deliver finasteride topically to hair follicles, potentially improving alopecia treatment with fewer side effects than oral forms.

This study found that topical melatonin solution was associated with positive effects on hair density and reduction in hair loss for androgenetic alopecia, with good tolerability reported in several clinical trials.

This study suggests that the methanol extract of Buxus wallichiana has promising antioxidant properties and may promote hair growth, with varying effectiveness depending on the dosage and application form.

This study concluded that oral and topical minoxidil have similar overall benefits in treating androgenetic alopecia, but topical minoxidil improved hair density more and had fewer adverse effects.

This study analyzed 57 medicinal and cosmetic preparations available in Poland for treating alopecia, finding that finasteride is the most common active ingredient, with many products being in tablet or shampoo form and categorized as prescription drugs and cosmetics.

This case report details two women with female pattern hair loss who experienced severe scalp allergic contact dermatitis from minoxidil, one due to the active ingredient and the other due to the vehicle.

This study found that a 1% Sandalore® solution reduced hair shedding and improved hair volume and anagen phase duration in women with telogen effluvium over 24 weeks, compared to placebo.

This study reported that the expression of sulfotransferase enzymes in hair follicles remained stable during treatment with topical minoxidil, indicating consistent metabolic activity throughout the treatment period.

This study reviews female hair loss conditions with a focus on diagnosis and treatment. It highlights female pattern hair loss as the most common form and emphasizes the need for personalized therapy, including topical minoxidil and, when appropriate, antiandrogen treatments.

Low-dose oral minoxidil may be a promising alternative to topical minoxidil for hair loss.

Combining low-level laser therapy with topical corticosteroids effectively improved Lichen Planopilaris symptoms.

This study observed that 70.2% of patients with androgenetic alopecia at a dermatologic clinic used complementary and alternative medicine, with topical applications being the most common form.

This study reports promising results for alopecia universalis treatment using a combination of systemic methotrexate and low-dose corticosteroids with topical minoxidil, though monitoring for side effects is necessary.

This study compared the effectiveness of topical finasteride, oral finasteride, and topical minoxidil over 12 months in postmenopausal women with androgenetic alopecia, exploring their therapeutic effects on this population. Results are not reported in the abstract.

This study formulated a minoxidil-loaded submicron emulsion-based topical gel, which demonstrated effective in vitro release, ex vivo permeation, and stability, suggesting it may offer a targeted treatment approach for alopecia compared to traditional methods.

Minoxidil solution helps hair regrowth in alopecia areata, with 5% being more effective.

In this study, the authors compared topical diphencyprone and tretinoin gel for treating alopecia totalis and universalis, but the abstract does not report any definitive clinical results.

This review discusses current topical treatments, natural products, and complementary therapies for androgenetic alopecia, but it reports no new clinical results.

A new method was created to accurately measure minoxidil and aminexil in hair loss treatments.